Kardigan, Inc. Common Stock - Asset Resilience Ratio
Kardigan, Inc. Common Stock (KARD) has an Asset Resilience Ratio of 59.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Kardigan, Inc. Common Stock's Asset Resilience Ratio has changed over time. See KARD financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Kardigan, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kardigan, Inc. Common Stock (KARD) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $205.56 Million | 59.04% |
| Total Liquid Assets | $205.56 Million | 59.04% |
Asset Resilience Insights
- Very High Liquidity: Kardigan, Inc. Common Stock maintains exceptional liquid asset reserves at 59.04% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kardigan, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Kardigan, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
NASDAQ:TRAXV |
Biotechnology | 13.07% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Evommune, Inc.
NYSE:EVMN |
Biotechnology | 46.74% |
Annual Asset Resilience Ratio for Kardigan, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Kardigan, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.94% | $226.50 Million | $390.94 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $63.53 Million | -- |
About Kardigan, Inc. Common Stock
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI… Read more